Upstream Bio (NASDAQ:UPB) Receives Buy Rating from HC Wainwright

Upstream Bio (NASDAQ:UPB)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $36.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 449.62% from the stock’s current price.

UPB has been the topic of several other reports. JPMorgan Chase & Co. lifted their price objective on Upstream Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, August 14th. Wall Street Zen downgraded shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Truist Financial dropped their price target on shares of Upstream Bio to $25.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Finally, Mizuho decreased their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $29.67.

Upstream Bio Stock Down 1.1%

Shares of NASDAQ:UPB opened at $6.55 on Wednesday. The company has a market capitalization of $358.74 million, a price-to-earnings ratio of -2.26 and a beta of 1.28. The company has a 50 day moving average of $6.96 and a two-hundred day moving average of $7.97. Upstream Bio has a 52-week low of $5.85 and a 52-week high of $33.68.

Upstream Bio (NASDAQ:UPB) last posted its earnings results on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. The business had revenue of $0.77 million for the quarter, compared to analysts’ expectations of $0.56 million. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. On average, equities analysts anticipate that Upstream Bio will post -2.86 earnings per share for the current year.

Institutional Investors Weigh In On Upstream Bio

A number of institutional investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio acquired a new stake in shares of Upstream Bio during the 2nd quarter valued at approximately $33,000. Persistent Asset Partners Ltd acquired a new position in Upstream Bio in the second quarter worth $34,000. BNP Paribas Financial Markets increased its stake in Upstream Bio by 229.8% during the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after purchasing an additional 2,158 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Upstream Bio by 83.0% during the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares during the period. Finally, Empowered Funds LLC acquired a new stake in shares of Upstream Bio during the fourth quarter worth $45,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.